Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ViaCyte, Inc.
Many industry leaders expect broad progress in the field of RNA technologies following the rapid and successful roll-out of mRNA vaccines against COVID-19 last year. Genetic medicines of various types, emerging platforms for tackling previously “undruggable” targets and the microbiome were among other areas singled out as areas to watch in 2022.
A new report from Informa's Meddevicetracker outlines the market drivers and competitive landscape for the carotid artery stents and embolic protection devices market.
A May recall of 25,000 Super Torque MB Angiographic Catheters with Radiopaque Marker Bands was given the high-risk classification by the US agency on 22 September.
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
- Drug Delivery
- Implantable Devices
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- BetaLogics Internal Venture